Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

Abstract excerpt

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients relapsing off-therapy. In all, 84 patients with CTCL and 47 with PTCL were enrolled. Responses occurred early, were...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous lymphoproliferative disorders research
• Share to Histone Deacetylase Inhibitors Research
• Share to T-cell and Retrovirus Studies